

Title (en)
3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes

Title (de)
3-Cyclyl-2-(4-Sulfamoyl-Phenyl)-N-Cyclyl-Propionamid-Derivate zur Behandlung von Störungen der Glucosetoleranz und Diabetes

Title (fr)
Dérivés de 3-cyclyl-2-(4-sulfamoyl-phenyl)-N-cyclyl-propionamide utiles dans le traitement de l'intolérance au glucose et du diabète

Publication
EP 2554540 A3 20130522 (EN)

Application
EP 11154054 A 20060928

Previously filed application
PCT/US2006/038200 20060928 WO

Priority
• EP 06804270 A 20060928
• US 72262805 P 20050930

Abstract (en)
[origin: WO2007041365A2] The present invention provides compounds of the formula (I); which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, type 2 diabetes and obesity.

IPC 8 full level
C07D 211/62 (2006.01); **C07D 213/75** (2006.01); **C07D 239/42** (2006.01); **C07D 241/04** (2006.01); **C07D 241/20** (2006.01); **C07D 277/46** (2006.01); **C07D 277/82** (2006.01); **C07D 513/04** (2006.01)

CPC (source: EP KR US)
A61K 31/47 (2013.01 - KR); **A61K 31/496** (2013.01 - KR); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 211/62** (2013.01 - KR); **C07D 213/75** (2013.01 - EP KR US); **C07D 213/80** (2013.01 - EP KR US); **C07D 215/38** (2013.01 - EP KR US); **C07D 217/22** (2013.01 - EP KR US); **C07D 231/56** (2013.01 - EP KR US); **C07D 235/30** (2013.01 - EP US); **C07D 237/20** (2013.01 - EP US); **C07D 239/42** (2013.01 - EP KR US); **C07D 241/20** (2013.01 - EP KR US); **C07D 257/06** (2013.01 - EP KR US); **C07D 277/46** (2013.01 - EP US); **C07D 277/56** (2013.01 - EP US); **C07D 277/82** (2013.01 - EP US); **C07D 285/135** (2013.01 - EP US); **C07D 513/04** (2013.01 - EP US)

Citation (search report)
• [X] WO 0058293 A2 20001005 - HOFFMANN LA ROCHE [CH]
• [X] WO 2004072031 A2 20040826 - OSI PHARM INC [US], et al
• [XP] WO 2005095418 A1 20051013 - NOVARTIS AG [CH], et al

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2007041365 A2 20070412; WO 2007041365 A3 20070621; WO 2007041365 B1 20070816; AR 056548 A1 20071010;
AU 2006297127 A1 20070412; AU 2006297127 B2 20110929; BR PI0616567 A2 20110621; CA 2623686 A1 20070412;
CN 101273015 A 20080924; EP 1934180 A2 20080625; EP 1934180 B1 20121205; EP 2554540 A2 20130206; EP 2554540 A3 20130522;
ES 2400962 T3 20130415; GT 200600429 A 20070430; JP 2009510110 A 20090312; KR 20080049081 A 20080603; PE 20070585 A1 20070724;
RU 2008116575 A 20091110; RU 2435757 C2 20111210; TW 200745037 A 20071216; US 2008318948 A1 20081225; US 7795257 B2 20100914

DOCDB simple family (application)
US 2006038200 W 20060928; AR P060104278 A 20060928; AU 2006297127 A 20060928; BR PI0616567 A 20060928; CA 2623686 A 20060928;
CN 200680035674 A 20060928; EP 06804270 A 20060928; EP 11154054 A 20060928; ES 06804270 T 20060928; GT 200600429 A 20060925;
JP 2008533702 A 20060928; KR 20087007628 A 20080328; PE 2006001180 A 20060928; RU 2008116575 A 20060928;
TW 95136299 A 20060929; US 8860806 A 20060928